Journal
FRONTIERS IN MEDICINE
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.701061
Keywords
tenofovir alafenamide; suboptimal response; HBeAg-positive chronic hepatitis B; monotherapy; case report
Categories
Funding
- National Natural Sciences Foundation [2019JJ30041, 82070613]
- Innovation-Driven Project of Central South University [2020CX044]
Ask authors/readers for more resources
This study reported two adult male patients with a suboptimal response to TAF monotherapy, which is an uncommon occurrence. Further long-term observations and extensive data are needed to evaluate the efficacy and safety of TAF, highlighting the importance of developing more robust novel direct-acting antivirals and immune therapies for HBV.
Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available